Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation therapy, both in combination with ongoing treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), in patients with treatment-resistant depression are unknown. METHODS: In an open-label, single-blind (with raters unaware of group assignments), multicenter, phase 3b, randomized, active-controlled trial, we assigned patients, in a 1:1 ratio, to receive flexible doses (according to the summary of product characteristics) of esketamine nasal spray (esketamine group) or extended-release quetiapine (quetiapine group), both in combination with an SSRI or SNRI. The primary end point was remission, defined as a score of 10 or less on the Montgomery-Åsberg Depression Rating Scale (MADRS), at week 8 (scores range from 0 to 60, with higher scores indicating more severe depression). The key secondary end point was no relapse through week 32 after remission at week 8. All patients were included in the analysis; patients who discontinued the trial treatment were considered as having had an unfavorable outcome (i.e., they were grouped with patients who did not have remission or who had a relapse). Analyses of the primary and key secondary end points were adjusted for age and number of treatment failures. RESULTS: Overall, 336 patients were assigned to the esketamine group and 340 to the quetiapine group. More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 patients [27.1%] vs. 60 of 340 patients [17.6%]; P = 0.003) and had no relapse through week 32 after remission at week 8 (73 of 336 patients [21.7%] vs. 48 of 340 patients [14.1%]). Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray. The adverse events were consistent with the established safety profiles of the trial treatments. CONCLUSIONS: In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8. (Funded by Janssen EMEA; ESCAPE-TRD ClinicalTrials.gov number, NCT04338321.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ESCAPE-TRD trial reported a comparatively smaller effect size for esketamine versus quetiapine (− 2.2 MADRS points; 95% CI, − 3.6 to − 0.8) at 32 weeks [19].”
In the citing paper
“At 8 weeks, esketamine nasal spray demonstrated superior efficacy [19].”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Self-citationDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Cited by
Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases
Huang, Q., Chen, Y., Zhang, W., Xia, X., Li, H., Qin, M., & Gao, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.054 · Cited by 167
Treatment with psychedelics is psychotherapy: beyond reductionism
Gründer, G., Brand, M., Mertens, L. J., Jungaberle, H., Kärtner, L., Scharf, D., Spangemacher, M., & Wolff, M. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00363-2 · Cited by 129
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
“…esketamine nasal spray adjunctive to a continuing SSRI or SNRI was superior to adjunctive extended-release quetiapine for the acute and continuation treatment of adults with TRD [remission at week 8; esketamine 27.1% (91/336) versus quetiapine 17.6% (60/340), adjusted P < 0.01] (Table 2) [128].”
InfluentialAdvances and future perspectives of intranasal drug delivery: A scientometric review
Xu, D. W., Song, X., Chen, X., Wang, J., & Cui, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.053 · Cited by 79
Saelens, J., Gramser, A., Watzal, V., Zarate, C. A., Lanzenberger, R., & Kraus, C. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-02044-5 · Cited by 51
Wu, X., Zang, R., Qiu, Y., Zhang, Y., Peng, J., Cheng, Z., Wei, S., Liu, M., & Diao, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060775 · Cited by 66
“Another clinical study has explored the esketamine nasal spray combined with a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor significantly improved remission and reduced relapse in treatment-resistant depression compared to quetiapine augmentation [21].”
Calder, C. N., Kwan, A. T. H., Teopiz, K. M., Wong, S., Rosenblat, J. D., Mansur, R. B., Rhee, T. G., Ho, R., Cao, B., & McIntyre, R. S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.039 · Cited by 42
McIntyre, R. S., Bitter, I., Buyze, J., Fagiolini, A. M., Godinov, Y., Gorwood, P. A. P. M., Ito, T., Oliveira-Maia, A. J., Vieta, E., Werner‐Kiechle, T., et al. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.05.009 · Cited by 37
Self-citationAn Astroglial Basis of Major Depressive Disorder: Molecular, Cellular, and Circuit Features
Lu, C., Ren, J., & Cao, X. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.07.017 · Cited by 37
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 37
Self-citationBoudieu, L., Mennetrier, M., Llorca, P., & Samalin, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122773 · Cited by 32
“…depressive symptoms in comparison with placebo groups in several short-term randomized placebo-controlled studies [30,31,33,35,38,39] and has shown superior remission rates at week 8 in comparison to extended-release quetiapine in a randomized active-controlled study of MDD patients with TRD [41].”
BackgroundMethodResultInfluentialSelf-citationRosso, G., d’Andrea, G., Barlati, S., Nicola, M. D., Andriola, I., Marcatili, M., Martiadis, V., Olivola, M., Mauro, S. D., Salvo, G. D., et al. (2025) · Current Neuropharmacology · doi:10.2174/011570159x337670241029062524 · Cited by 27
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Self-citationGuo, Q., Guo, L., Yong, W., & Shang, S. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116018 · Cited by 30
Ingrosso, G., Cleare, A. J., & Juruena, M. F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303597 · Cited by 28
Overcoming the myths of esketamine administration: different and not difficult
Buchmayer, F., & Kasper, S. F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1279657 · Cited by 25
“In patients with Treatment-Resistant Depression (TRD), esketamine demonstrates significant superiority over extended-release quetiapine (quetiapine XR) as an adjunctive treatment in terms of response, remission, and relapse prevention over a period of 32 weeks (43).”
BackgroundHumphreys, K. N., Korthuis, P. T., Stjepanović, D., & Hall, W. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-020124-023532 · Cited by 32
Hu, J., Lian, Z., Weng, Z., Xu, Z., Gao, J. Y., Liu, Y., Luo, T., & Wang, X. (2024) · Advanced Materials · doi:10.1002/adma.202405547 · Cited by 22
Esketamine in depression: putative biomarkers from clinical research
Johnston, J. N., Zarate, C. A., & Kvarta, M. D. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01865-1 · Cited by 23
Ju, M., Zhang, Z., Gao, F., Chen, G., Zhao, S., Wang, D., Wang, H., Jia, Y., Shen, L., Yuan, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402219 · Cited by 21
Samalin, L., Mékaoui, L., Rothärmel, M., Sauvaget, A., Wicart, C., Dupin, J., Cohignac, V., & Gaudre-Wattinne, E. (2024) · Depression and Anxiety · doi:10.1155/2024/7262794 · Cited by 22
“In the ESCAPE-TRD trial, the absolute rate of remission was 27.1 % at Week 8 [18].”
InfluentialConstantino, J. L., Godschalk, M., van Dalfsen, J. H., Veraart, J. K. E., Spijker, J., van Exel, E. R., Schoevers, R. A., & Kamphuis, J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116355 · Cited by 23
Namiot, E. D., Smirnovová, D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03031-6 · Cited by 27
“These targets offer new prospects for treating drug-resistant depression.”
BackgroundCleare, A. J., Kerr-Gaffney, J., Goldsmith, K., Zenasni, Z., Yaziji, N., Jin, H., Colasanti, A., Geddes, J. R., Kessler, D., McAllister-Williams, R. H., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00028-8 · Cited by 18
Self-citationVieta, E., Ahmed, N., Arango, C., Cleare, A. J., Demyttenaere, K., Dold, M., Ito, T., Kambarov, Y., Krüger, S., Llorca, P., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.12.013 · Cited by 23
Self-citationResearch progress on antidepressant effects and mechanisms of berberine
Gao, Y., Nie, K., Wang, H., Dong, H., & Tang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1331440 · Cited by 25
Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., Luca, S. M. D., & Xu, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03033-4 · Cited by 25
Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention—Mechanisms and Pharmacodynamics
Song, H., Luo, Y., & Fang, L. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s486118 · Cited by 21
Kumari, S., Chaudhry, H. A., Sagot, A. J., Doumas, S. J., Abdullah, H. M., Alcera, E. C., Solhkhah, R., & Afzal, S. (2024) · Cureus · doi:10.7759/cureus.53987 · Cited by 28
“[32].”
BackgroundMethodInfluentialPsychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001724 · Cited by 17
“54 TRD treatment approaches have proven expensive and underwhelming and not all have been approved based on TRD efficacy.”
BackgroundCai, J., Chen, X., Jin, Z., Chi, Z., & Xiong, J. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02733-0 · Cited by 22
Kwan, A. T. H., Lakhani, M., Teopiz, K. M., Wong, S., Le, G. H., Ho, R., Rhee, T. G., Cao, B., Rosenblat, J. D., Mansur, R. B., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.01.054 · Cited by 16
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
Cubała, W. J., Bajbouj, M., Bauer, M., Baune, B. T., Cardoner, N., Devlin, F., Doolin, K., Herrero, R. D., Elices, M., Feeney, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0096 · Cited by 20
Self-citationZheng, H., Zhang, P., Shi, S., Zhang, X., Cai, Q., & Gong, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-54617-5 · Cited by 16
“Lastly, esketamine is used to treat depression 27,28 , and the anti-depressive effects could be masked by anesthesia 29 .”
MethodSackeïm, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., George, M. S., McAllister-Williams, H., Prudic, J., Thase, M. E., Young, A. H., & Rush, A. J. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.046 · Cited by 17
Self-citationBenefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Price, M. Z., & Price, R. L. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100104 · Cited by 16
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 16
Biomarker innovations in precision psychiatry diagnostics and treatment strategies
Kas, M. J., Kim, Q., Sand, M. S., Kozak, R., Tunbridge, E. M., Oquendo, M. A., Tamminga, C. A., Koutsouleris, N., Knudsen, G. M., Penninx, B. W. J. H., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112762 · Cited by 18
Self-citationEfficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)
Olivier, B., & Olivier, J. D. A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_3 · Cited by 13
Tao, Q.-Y., Liu, D., Wang, S., Wang, X., Ouyang, R.-N., Niu, J.-Y., Ning, R., & Yu, J. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s481173 · Cited by 16
“6,7 Current research about esketamine primarily focuses on its nasal spray use in treatment-resistant depression, 8,9 it is frequently utilized in specific anesthesia scenarios due to its higher bioavailability, rapid metabolism, potent analgesic properties, and fewer adverse effects compared to…”
Is there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 18
The NMDA receptor subunit GluN2D is a potential target for rapid antidepressant action
Vestring, S., Veleanu, M., Perez, M. C., Schuberth, L. E., Bronnec, M., Li, A., Würz, L. M., Erdogdu, F., Stocker, J., Moos, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66774-w · Cited by 13
“This mightexplainthesustainedclinicaleffectsofKETforseveraldaysafter a single application or much longer after repeated applications 3,7,94,95 .”
New and emerging pharmacologic treatments for MDD
Uyar, A., & Gönül, A. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621887 · Cited by 20
Comparing the adverse effects of ketamine and esketamine between genders using FAERS data
Yang, X., & Chen, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1329436 · Cited by 16
“The most common adverse reactions in the esketamine group include dizziness, nausea, drowsiness, etc (Reif et al., 2023).”
BackgroundMolero, P., Ibáñez, Á., de Diego-Adeliño, J., Ramos‐Quiroga, J. A., Dorado, M. G., Rengel, P. M. L., & Sáiz, P. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03149-z · Cited by 15
“Although difficult to compare, this sample is likely to be more difficult to treat than those included in the TRANSFORM 1 and 2 trials [23, 24] and than those in the ESCAPE‑TRD trial, a head‑to‑head comparison with quetiapine [39].”
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression
Freudenberg, F., Reif-Leonhard, C., & Reif, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01875-z · Cited by 15
Self-citationYoung, A. H., Llorca, P.-M., Fagiolini, A., Falkai, P., Cardoner, N., Nielsen, R. E., Blomqvist, O., Godinov, Y., Rive, B., Diels, J., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.124 · Cited by 9
Self-citationPsychedelics: The pathway to implementation in the European healthcare systems
Gründer, G., Mertens, L. J., Spangemacher, M., Meyer‐Lindenberg, A., & Jungaberle, H. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.11.007 · Cited by 11
Colosimo, F. A., Borsellino, P., Krider, R. I., Márquez, R., & Vida, T. A. (2024) · Psychoactives · doi:10.3390/psychoactives3010007 · Cited by 11
“Additionally, clinical recommendations still include ketamine as an adjunct or for use in treatment-resistant depression or in cases of depression with imminent suicidality [183–186].”
BackgroundKwan, A. T. H., Rosenblat, J. D., Mansur, R. B., Teopiz, K. M., & McIntyre, R. S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.116 · Cited by 12
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., Teopiz, K. M., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2368827 · Cited by 16
“Moreover, esketamine is superior to quetiapine XR in the short-and intermediate-term outcome in adults with TRD as well as treatment as usual with real-world evidence data [3–5].”
Chepke, C., Shelton, R. C., Sanacora, G., Doherty, T., Tsytsik, P., & Parker, N. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae058 · Cited by 12
Niu, X., Zheng, Y., Wang, W., Zhang, L., Wang, S., Lu, X., Wang, J., Yang, G., Zhao, T. C., Li, Q., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70145 · Cited by 10
“Approximately half of the patients in the ESK group achieved remission, and two-thirds responded to treatment by Week 32, underscoring the significance of ESK in treating treatment-resistant depression [41].”
Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials
Wang, Z., Jiang, L., Ma, W., Li, X., Gao, Q., Lian, S., & Yu, W. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3555 · Cited by 15
“In addition, the ECSCAPE-TRD (Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression) study has recently demonstrated the favorable long-term efficacy of esketamine nasal spray in controlling symptoms of TRD. 19 This study is distinct from previous studies that primarily focused on short-term effe…”
InfluentialChen, Z., Gao, Y., Gao, C. Q., Zhang, Y., Zhang, L., Zhang, H., Wu, Q., Jin, Y., Guo, N., Liu, L., et al. (2025) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2025.101567 · Cited by 19
Gutiérrez-Rojas, L., Vendrell-Serres, J., Ramos‐Quiroga, J. A., Etxeandia-Pradera, J.-I., Aguilar, E. J., de Santiago-Díaz, A. I., Hernández-Huerta, D., Tordera, V., Ventoso, C. V., Bolívar, M., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241267837 · Cited by 13
Zhang, X., Duan, P., Sun, Y., & Na, Q. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321892 · Cited by 14
“The FDA updated the approval of intranasal esketamine can improve adults with major depression and suicidal ideation and behavior [35].”
Klučková, T., Nikolič, M., Tylš, F., Viktorin, V., Vejmola, Č., Viktorinová, M., Bravermanová, A., Androvičová, R., Andrashko, V., Korčák, J., et al. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00742-5 · Cited by 10
Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review
Kerr‐Gaffney, J., Tröger, A., Caulfield, A., Ritter, P. S., Rucker, J., & Young, A. H. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251350267 · Cited by 9
Self-citationTreatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects
Mora, F., Ramos‐Quiroga, J. A., Baca‐García, E., Crespo, J. M., Gutiérrez-Rojas, L., Madrazo, A., Pérez-Costillas, L., Sáiz, P. A., Tordera, V., & Vieta, E. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1623659 · Cited by 11
Petrozzi, B. P., Spangemacher, M., Deicher, A., Drews, L., Defert, J., Silva-Colmenero, A. Y., Wein, P., Riedinger, E., Gründer, G., Gilles, M., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1415505 · Cited by 12
Psilocybin as a disease-modifying drug—a salutogenic approach in psychiatry
Spangemacher, M., Mertens, L. J., Färber, L. V., Jungaberle, A., Jungaberle, H., & Gründer, G. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0224 · Cited by 12
Fan, X., Wang, H., Lv, X., Wang, Q., Yu, B., Li, X., Li, L., Zhang, Y., Ma, N., Lü, Q., et al. (2025) · Brain Sciences · doi:10.3390/brainsci15030236 · Cited by 8
Miedlich, S. U., & Lamberti, J. S. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15301 · Cited by 13
Veraart, J. K. E., Smith-Apeldoorn, S. Y., van der Meij, A., Spijker, J., Schoevers, R. A., & Kamphuis, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251332831 · Cited by 10
Non-response to short-term ketamine use for treatment-resistant depression
Walaszek, M., Cubała, W. J., Kachlik, Z., Pastuszak, M., Pastuszak, K., & Kwaśny, A. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00730-9 · Cited by 7
Huang, X. D., Li, X., Sun, Y., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s490423 · Cited by 7
Liu, T., Wu, J., Huang, P., Cheng, W.-L., & Lai, C. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.07.006 · Cited by 10
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04435-x · Cited by 6
McIntyre, R. S., Stahl, S. M., Shim, S. R., Pompili, M., Goldberg, J. F., Correll, C. U., Kwan, A. T. H., Dri, C. E., Xu, H., Vinberg, M., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0658 · Cited by 12
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 9
Self-citationLi, K., Chai, Z., Deng, C., Niu, G., Geng, X., Zhang, Y., Wang, Y., & Wang, T. (2025) · BMC Anesthesiology · doi:10.1186/s12871-024-02846-6 · Cited by 8
“Esketamine, the S-enantiomer of ketamine, exhibits superior and quicker sedative and analgesic effects along with a higher safety profile due to its larger affinity for NMDA receptors [8, 9].”
Zhang, Y., Wang, Y., Wang, H., Bian, L., Gao, F., Yao, H., & Xie, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c19377 · Cited by 9
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Serefko, A., Lachowicz-Radulska, J., Szopa, A., Herbet, M., Czylkowska, A., Ignatiuk, K., Dołoto, A., Szewczyk, B., Wośko, S., Wróbel, A., et al. (2025) · Molecules · doi:10.3390/molecules30030519 · Cited by 8
“Similarly, esketamine (a nonselective, noncompetitive antagonist of N-methyl-D-aspartate receptors) administered as nasal spray is used in conjunction with oral SSRIs or SNRIs in treatment-resistant depression [34].”
Frivaldszky, L., Lőrincz, K., Hoferica, J., Hegyi, P., Ács, N., Melczer, Z., Fehérvári, P., & Keszthelyi, M. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.02.021 · Cited by 6
Tsai, D. H., Yang, A. S., Wong, Z.-X., Chuang, A. T.-M., Cheng, M. C., Shen, C., Shao, S., & Lai, E. C. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.283 · Cited by 4
“27 However, there were some limitations to this study.”
Shi, H., Zheng, C., Shou, H., & Zhu, B. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119631 · Cited by 9
Wang, S., Hao, W., Fan, H., Wu, J., & Wu, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663348 · Cited by 6
“This biochemical association aligns with contemporary mechanistic studies (Medeiros et al., 2022; Reif et al., 2023).”
Kaster, T. S., Dai, Y., Vila‐Rodriguez, F., Downar, J. H., Daskalakis, Z. J., Blumberger, D. M., & Rhee, T. G. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103609 · Cited by 9
Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk
McIntyre, R. S. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.019 · Cited by 7
Chen, X., Zhou, R., Lan, L., Zhu, L., Chen, C., Zhang, X., Han, J., & Xia, L. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s463028 · Cited by 5
“28,37 Therefore, the incidence and degree of related adverse effects were recorded in detail throughout the treatment process, and the data collected were analyzed objectively.”
MethodKim, S., Yang, S., Jung, J., Choi, J., Kang, M., & Joo, J. (2025) · Advanced Science · doi:10.1002/advs.202413786 · Cited by 10
Hong, X., Xu, S., Sun, G., Liu, Y., Yi, W., Hu, Q., Li, W., Liu, J., Wu, F., Yu, M., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.077 · Cited by 5
Ramos‐Quiroga, J. A., Mora, F., Arostegui, S., Cardoner, N., Etxeandia-Pradera, J.-I., Gómez-Juanes, R., Gómez‐Revuelta, M., Montes, J. M. G., & Vieta, E. (2025) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2025.100313 · Cited by 4
Yakimov, V., Neuwinger, L., Weber, M. M., Brantl, M., Maurus, I., Sautner, J., John, M., Karslı, B., Hasanaj, G., Bungard, A., et al. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02100-1 · Cited by 4
“This is especially important in light of new emerging treatments with differ - ent mechanisms of action [79, 80].”
Insights for the Next Generation of Ketamine for the Treatment of Depressive Disorder
Martins, A. C. F., Badenoch, B., & Gomes, R. D. S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02467 · Cited by 4
Mathew, S. J., & Murphy, N. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241177 · Cited by 4
Monn, A., Eicher, C., Rüesch, A., Kronenberg, G., Offenhammer, B., Adank, A., de Bardeci, M., Ip, C.-T., Scheerer, H., Schaekel, L., et al. (2025) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2025.112001 · Cited by 7
Huang, C., Hu, L., Wu, L., Geng, F., Wong, G. T. C., Zhang, Y., Reif, A., Bao, Y., Xue, Q., & Lü, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03320-6 · Cited by 17
Self-citationAugmentation in depression: Esketamine, a new standard?
Rosenblat, J. D., & McIntyre, R. S. (2023) · Med · doi:10.1016/j.medj.2023.11.002 · Cited by 4
Lake‐Bakaar, G., Milgrom, B., Kulig, C. C., et al. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.02.004 · Cited by 4
Hung, K.-C., Kao, C., Lai, Y., Chen, J.-Y., Lin, C.-H., Ko, C., Lin, C., & Chen, I. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310751 · Cited by 9
Clemens, K., Zhdanava, M., Teeple, A., Voegel, A., Joshi, K., Shah, A., Chen, C., & Pilon, D. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.24240 · Cited by 5
Liu, C., Wang, Y., Yin, Y.-W., Wang, P., Ji, X., Sun, J., Zhao, S., Jia, Y., Liu, S., & Zhou, Z. (2025) · Journal of Pain Research · doi:10.2147/jpr.s498499 · Cited by 5
Kavakbasi, E., Rosemann, K., Yilmaz, M., Berndt, H., & Baune, B. T. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02041-9 · Cited by 4
Xuesong, Xu, Y., Xiong, H.-P., Li-Tang, Liu, Q.-R., & Zhang, D. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116849 · Cited by 5
Progress in the Application of Esketamine During the Perioperative Period
Wang, J., Hu, Q., Cao, R.-Y., Liu, W.-K., Guo, M., Lin, Y., Zhong, M., Liang, W., & Wang, L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s579462 · Cited by 8
“14,15 The primary metabolic pathway of esketamine involves biotransformation by hepatic cytochrome P450 (CYP450) enzymes (along with other auxiliary pathways) into norketamine and its hydroxylated derivatives.”
Reif, A., Anıl, Y. A., Bitter, I., Buyze, J., Frey, R., Fu, D. J., Godinov, Y., Haggström, L., Kambarov, Y., Nielsen, R., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112801 · Cited by 4
Self-citation
Metadata
- Authors
- Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., Messer, T., Mulhern-Haughey, S., Rive, B., von Holt, C., Young, A. H., & Godinov, Y.
- Affiliations
- Semmelweis University (HU)
- From the Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University Hospital, Goethe University Frankfurt, and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt (A.R.), Danuvius Klinik, Technische Universität München, Pfaffenhofen an der Ilm (T.M.), and Janssen Germany (K.C.) and Janssen EMEA (C.H.), Neuss — all in Germany; the Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary (I.B.); Janssen Pharmaceutica (J.B.) and Janssen EMEA (Y.K.) — both in Beerse, Belgium; the Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna (R.F.); Janssen Research and Development, New Jersey (D.-J.F.); Janssen EMEA, High Wycombe (T.I.), the Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, and South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham (A.H.Y.) — all in the United Kingdom; CHU Clermont-Ferrand, Departme...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-10-05
- Volume
- 389
- Issue
- 14
- Pages
- 1298-1309
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387324672
- Cited by
- 222
- References
- 29
- Citations by year
- 2026: 76 · 2025: 80 · 2024: 58 · 2023: 8
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Janssen EMEA
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, quetiapine, treatment-resistant depression, augmentation therapy, remission, relapse prevention, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressant efficacy, adverse events, NMDA receptor antagonists, ketamine, atypical antipsychotics, Montgomery-Asberg Depression Rating Scale, treatment response
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Quetiapine Fumarate, Antidepressive Agents, Delayed-Action Preparations, Depression, Drug Therapy, Combination, Humans, Ketamine, Recurrence, Single-Blind Method, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.